BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. (June 2015)

• Record Type: Journal Article
• Authors: Colle, Romain; Deflesselle, Eric; Martin, Séverine; David, Denis J; Hardy, Patrick; Taranu, Adéla; Falissard, Bruno; Verstuyft, Céline; Corruble, Emmanuelle
• Is Part Of: Pharmacogenomics. Volume 16:Number 9(2015)
• Page Start: 997
• Page End: 1013
• Publication Date: 2015-06
• Subjects: antidepressant remission -- antidepressant response -- BDNF -- major depressive disorder -- major depressive episode -- PNTR75 -- single nucleotide polymorphism -- TRKB; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.15.56
• Languages: English
• ISSNs: 1462-2416

Abstract

We propose an extensive review of the literature about BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. Five genome-wide association studies and 30 association studies were included. Twenty seven studies focused on the Val66Met polymorphism (rs6265), the Met allele being associated with a higher antidepressant efficacy only in Asian patients. Other BDNF/TRKB/P75NTR polymorphisms ( BDNF : rs7103411, rs7124442, rs908867, rs2049046, rs61888800, rs10501087, rs1491850; TRKB : rs10868223, rs11140778, rs1565445, rs1659412; P75NTR : rs2072446) were reported to be associated with antidepressant efficacy but these results were not replicated. Finally, there are 15 positive studies among 30 studies regarding BDNF/TRKB/P75NTR polymorphisms. The only SNP which benefits of at least three positive studies is the BDNF Val66Met polymorphism (rs6265). Consequently, with a lack of good and consistent studies, the clinical utility of BDNF in treatment selection is far from clear. We propose several recommendations for further studies.